The impact of serum uric acid on cardiovascular outcomes in the LIFE study Academic Article uri icon

Overview

MeSH Major

  • Antihypertensive Agents
  • Cardiovascular Diseases
  • Hypertension, Renal
  • Losartan
  • Uric Acid

abstract

  • The increase in SUA over 4.8 years in the LIFE study was attenuated by losartan compared with atenolol treatment, appearing to explain 29% of the treatment effect on the primary composite end point. The association between SUA and events was stronger in women than in men with or without adjustment of FRS.

publication date

  • March 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1523-1755.2004.00484.x

PubMed ID

  • 14871425

Additional Document Info

start page

  • 1041

end page

  • 9

volume

  • 65

number

  • 3